Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
31 Oct 2022
31 Oct 2022
Historique:
received:
05
08
2021
accepted:
08
09
2022
entrez:
1
11
2022
pubmed:
2
11
2022
medline:
2
11
2022
Statut:
epublish
Résumé
The increasing global impact of dengue underscores the need for a dengue virus (DENV) vaccine. We assessed B-cell and T-cell responses following vaccination with four formulations of a tetravalent dengue purified inactivated vaccine (DPIV) in dengue-primed and dengue-naive adults from two studies (NCT01666652, NCT01702857). Frequencies of DPIV-induced memory B cells specific to each DENV serotype remained high up to 12 months post-vaccination, and were higher in the dengue-primed than dengue-naive adults. A subsequent DPIV booster dose induced strong anamnestic B-cell responses. Multifunctional CD4+ T cells (predominantly expressing IL-2) were induced by DPIV, with higher frequencies in dengue-primed adults. DPIV-induced CD4+ T cells also demonstrated in vitro proliferative capacity and antigen-specific production of GM-CSF, IFN-γ, and IL-13. CD8+ T-cell responses were undetectable in dengue-naive adults and low in dengue-primed individuals. B- and T-cell responses persisted up to 12 months post-vaccination in both dengue-primed and dengue-naive adults.
Identifiants
pubmed: 36316335
doi: 10.1038/s41541-022-00537-2
pii: 10.1038/s41541-022-00537-2
pmc: PMC9622737
doi:
Types de publication
Journal Article
Langues
eng
Pagination
132Informations de copyright
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022.
Références
J Virol. 2006 Dec;80(23):11756-66
pubmed: 16971435
J R Soc Interface. 2013 Jul 03;10(86):20130414
pubmed: 23825116
Am J Trop Med Hyg. 2015 Apr;92(4):698-708
pubmed: 25646261
Am J Trop Med Hyg. 2018 May;98(5):1435-1443
pubmed: 29512481
Int J Environ Res Public Health. 2018 Dec 07;15(12):
pubmed: 30544521
Hum Vaccin Immunother. 2013 Nov;9(11):2317-25
pubmed: 23839107
Vaccine. 2008 Oct 23;26(45):5712-21
pubmed: 18762226
Am J Trop Med Hyg. 2017 Jun;96(6):1325-1337
pubmed: 28719287
Am J Trop Med Hyg. 2020 Jul;103(1):132-141
pubmed: 32342848
Hum Vaccin Immunother. 2017 May 4;13(5):1059-1072
pubmed: 28281864
Lancet. 2019 Jan 26;393(10169):350-363
pubmed: 30696575
Methods Mol Biol. 2018;1808:151-163
pubmed: 29956181
mSphere. 2020 Jan 22;5(1):
pubmed: 31969476
Am J Trop Med Hyg. 2020 May;102(5):951-954
pubmed: 32124728
Lancet Infect Dis. 2017 Mar;17(3):e70-e78
pubmed: 28185869
J Immunol Methods. 2004 Mar;286(1-2):111-22
pubmed: 15087226
Lancet Infect Dis. 2016 Aug;16(8):935-41
pubmed: 27091092
Hum Vaccin Immunother. 2019;15(10):2315-2327
pubmed: 30724660
N Engl J Med. 2018 Jul 26;379(4):327-340
pubmed: 29897841
Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53
pubmed: 23580623
Nat Rev Microbiol. 2016 Jan;14(1):45-54
pubmed: 26639777
Vaccines (Basel). 2020 Feb 02;8(1):
pubmed: 32024238